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Sequestration of Plasmodium falciparum-infected erythrocytes (Pf-iEs) in the microvasculature of vital organs plays a key role
in the pathogenesis of life-threatening malaria complications, such as cerebral malaria andmalaria in pregnancy. This phenome-
non is marked by the cytoadhesion of Pf-iEs to host receptors on the surfaces of endothelial cells, on noninfected erythrocytes,
and in the placental trophoblast; therefore, these sites are potential targets for antiadhesion therapies. In this context, glycosami-
noglycans (GAGs), including heparin, have shown the ability to inhibit Pf-iE cytoadherence and growth. Nevertheless, the use of
heparin was discontinued due to serious side effects, such as bleeding. Other GAG-based therapies were hampered due to the
potential risk of contamination with prions and viruses, as some GAGs are isolated frommammals. In this context, we investi-
gated the effects andmechanism of action of fucosylated chondroitin sulfate (FucCS), a unique and highly sulfated GAG isolated
from the sea cucumber, with respect to P. falciparum cytoadhesion and development. FucCS was effective in inhibiting the cy-
toadherence of Pf-iEs to human lung endothelial cells and placenta cryosections under static and flow conditions. Removal of the
sulfated fucose branches of the FucCS structure virtually abolished the inhibitory effects of FucCS. Importantly, FucCS rapidly
disrupted rosettes at high levels, and it was also able to block parasite development by interfering with merozoite invasion. Col-
lectively, these findings highlight the potential of FucCS as a candidate for adjunct therapy against severe malaria.
Malaria still accounts for nearly one million deaths annually(1), and it is often associated with severe complications,
such as cerebral malaria (CM) and malaria in pregnancy (MiP).
MiP affects 125 million women each year and results in 200,000
infant deaths (2, 3). Despite recent advances inmalaria treatment,
CM still has mortality rates of 15 to 20%, even after appropriate
antimalarial treatment (4, 5), and pregnant women are also at risk
for additional complications (e.g., CM) (6).
High levels of proinflammatory cytokines are commonly ob-
served in patients with CM (7, 8) and MiP (9–11), and patholog-
ical studies have revealed sequestration of Plasmodium falcipa-
rum-infected erythrocytes (Pf-iEs) in the brain microvasculature
(12, 13) and in the placenta (14–16). Recently, sequestration of
Pf-iEs in the brain microvasculature has been associated with se-
vere CM and death (17). Additionally, poor outcomes for both
mother and fetus in MiP are related to greater amounts of Pf-iEs
sequestered in the placenta (18, 19).
Sequestration results in the removal of mature Pf-iE forms
(20 h after reinvasion) from the peripheral circulation, as a con-
sequence of the adhesion of parasitized cells to the capillary and
postcapillary endothelium and to placental trophoblasts (15, 16,
20, 21). Specific adhesion of Pf-iEs during the early ring stage has
also been observed in vitro (22). Another major adhesion pheno-
type is rosetting, which results from the binding of noninfected
erythrocytes (niEs) to Pf-iEs and has been associated with all se-
vere malarial syndromes (23), including CM (23–28). In contrast,
no significant correlation between rosetting and disease severity
has been reported for isolates from Papua, New Guinea (29), in-
dicating that geographic variations in parasite strains matter (29).
Recently, a pivotal role for cytoadherence through the endothelial
protein C receptor in the development of severe malaria was de-
scribed (30). Cytoadhesion of Pf-iEs is mediated by members of
the P. falciparum membrane protein 1 (PfEMP-1) family, which
mediates parasite interactions with various host receptors, includ-
ing CD36 (31), intercellular adhesion molecule 1 (ICAM-1) (32),
and chondroitin sulfate A (CSA) (33, 34), a receptor frequently
associated with MiP (15, 33, 35)
Glycosaminoglycans (GAGs), including heparin, have been
employed as a strategy to prevent malaria complications due to
their abilities to inhibit parasite cytoadhesion, to block invasion,
and to disrupt rosettes (36–46). However, the side effects of hep-
arin, mostly serious bleeding (47), and the potential risk of con-
tamination (because some GAGs are obtained from mammals)
have hampered GAG-based adjunct therapies. Recently, we have
shown that fucosylated chondroitin sulfate (FucCS), a GAG iso-
lated from the marine invertebrate sea cucumber, contains a cen-
tral chondroitin sulfate backbone like mammalian GAGs; how-
ever, FucCS has sulfated fucose branches (48–50), displays
anticoagulant activity (48), and prevents thrombosis (51). FucCS
also reduces the recruitment of inflammatory cells, most likely by
inhibiting cell adhesion to the host endothelium (52). Here, we
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investigate the effects of FucCS on the adhesion of Pf-iEs to endo-
thelial cells and placenta cryosections, as well as its abilities to
disrupt rosettes and to block parasite invasion.
MATERIALS AND METHODS
Native and chemically modified FucCS. Native fucosylated chondroitin
sulfate was extracted from the bodywall of sea cucumbers (Ludwigothurea
grisea), which were freshly collected fromGuanabara Bay (Rio de Janeiro,
Brazil). FucCS was extracted by papain digestion, and purification was
performed as described previously (49, 50). The FucCS backbone is made
up of repeating disaccharide units of alternating -D-glucuronic acid and
N-acetyl--D-galactosamine, which is the same structure as mammalian
chondroitin sulfate (Fig. 1A). Partial removal of sulfated fucose branches
from the fucosylated chondroitin sulfate, yielding defucosylated chon-
droitin sulfate (deFucCS) (Fig. 1B), was achieved by mild acid hydrolysis,
as described elsewhere (48). Carboxyl-reduced chondroitin sulfate
(CRFucCS) was obtained from reduction of the hexuronic acid carboxyl
groups in the polysaccharide with 1-ethyl-3-(3-imethylaminopropyl)car-
bodiimide-NaBH4 (50, 53) (Fig. 1C).
Cytotoxicity assays. FucCS cytotoxicity was evaluated in hepatocellu-
lar carcinoma (HepG2) cells with theMTT [3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide] (Sigma-Aldrich) assay. Briefly, cells
were cultivated inDulbecco’smodified Eagle’s medium (DMEM) (Nutri-
cell, Brazil) supplementedwith 10% fetal bovine serum, penicillin (1 unit/
ml), and streptomycin (1 unit/ml), in a humidified atmosphere of 5%
CO2 at 37°C. HepG2 cells were seeded into 96-well plates at a density of
2 104 cells per well and were incubated with different concentrations of
FucCS. After 48 h, a solution of 5 mg/ml MTT was added, the cells were
incubated for 4 h, and the resulting formazan crystals were resuspended in
50 l of isopropanol. Absorbance at 590 nm (A590) of the cells, with
medium alone (control) or different concentrations of FucCS, was deter-
mined by spectrophotometry (Asys Expert Plus, United Kingdom). Tox-
icity was determined as percent inhibition, which was calculated accord-
ing to the following formula: percent inhibition [1 (At/Ac)] 100.At
and Ac refer to the absorbance of experimentally tested samples (FucCS)
and control samples (medium), respectively. FucCS toxicity was also de-
termined in noninfected erythrocytes (niEs) incubated in the presence or
absence (control) of FucCS. After 48 h of incubation at 37°C under con-
ditions similar to those used for P. falciparum growth, red blood cell den-
sity (RBCD) was determined by counting the intact cells in a Neubauer
chamber. The percent RBCD was calculated with the following formula:
percent RBCD  [1  (no. of niEs treated with FucCS/no. of niEs not
treated)]  100. Nontoxic samples were those in which no significant
inhibition of HepG2 cell growth or RBCD, relative to controls, was ob-
served.
Cultivation of laboratory strains and clinical isolates of P. falci-
parum-infected erythrocytes. In this work, we used P. falciparum strains
FCR3 (54, 55) and FCR3S1.2 (56). FCR3S1.2 is a highly rosetting and
autoagglutinating parasite, kindly provided by Mats Wahlgren (Karolin-
ska Institute, Stockholm, Sweden). The rosetting rate was kept at 75%
by centrifugation on Ficoll-Paque (GE, Germany), as described previ-
ously (56). For some of the cytoadhesion assays, we used two fresh P.
falciparum isolates (Pf38A and PfKA) that were recently harvested from
infected patients in Acre State (western Amazon Basin of Brazil). All Pf-iE
strains and isolates were cultured as described previously (57). Briefly,
Pf-iEs were cultivated in fresh type O human erythrocytes (Blood Cen-
ter, Universidade Estadual de Campinas) and suspended at a final hemat-
ocrit level of 4% in complete parasite medium (RPMI 1640 medium sup-
plemented with L-glutamine, 25 mM HEPES, 2 g/liter glucose, and 10%
homologous human plasma [pH 7.4]).
Selection ofmonophenotypicP. falciparumparasites.The following
cell types were used in this study: human lung endothelial cells (HLECs)
(58, 59) adapted for culture from primary explants and Chinese hamster
ovary (CHO) cells transfected with human ICAM-1 (CHO-ICAM) or
FIG 1 Chemical structures of fucosylated chondroitin sulfate and its modified forms. (A) Native FucCS. (B) Defucosylated chondroitin sulfate. (C) Carboxyl-
reduced chondroitin sulfate. FucCS contains a central core with a chondroitin sulfate-like structure and branches of 2,4-disulfated fucose branches. These
branches are easily removed by mild acid hydrolysis, yielding the defucosylated form. The glucuronic acid units found in the central core may be reduced and
form glucose units in the carboxyl-reduced form of FucCS.
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CD36 (CHO-CD36) (60). HLECs, CHO cells, and FCR3 parasites were
kindly donated by Jürg Gysin and Artur Scherf (Institute Pasteur, Paris,
France). FCR3 parasites that adhered to CSA (Pf-iEsCSA) were selected by
panning (5 rounds) on HLECs (61, 62) with the addition of soluble CSA
(100 mg/ml; Sigma-Aldrich). Briefly, enriched P. falciparum FCR3 para-
sites were incubated over confluent HLEC monolayers in cytoadhesion
medium (RPMI 1640 medium [pH 6.8]) for 1 h at 37°C. Cells were then
washed extensively with cytoadhesion medium to remove nonadherent
Pf-iEs. For specific elution of CSA-binders, soluble CSA (100 g/ml;
Sigma-Aldrich) was added and detached parasites were recultured.
Monophenotypic Pf-iEs capable of binding to ICAM-1 (Pf-iEsICAM) or
CD36 (Pf-iEsCD36) were obtained after panning (5 rounds) of mature-
stage Pf-iEs on CHO-ICAMor CHO-CD36 cells, respectively (58, 63). To
ensure selection of monophenotypic Pf-iEsCSA, static cytoadhesion assays
were performed with HLECs that had been previously treated with chon-
droitinase-ABC (0.5 U/ml; Sigma-Aldrich) or by incubation with soluble
CSA. High-level expression of var2csa-related transcripts in selected Pf-
iEsCSA was confirmed by quantitative reverse transcription-PCR (qRT-
PCR) using cDNA from ring-stage parasites as a template and oligonucle-
otides specific for the genes PFL0020c, PFD0995c/PFD1000c, and
PFL0030w (var2csa) and the internal control targetsPF07_0073 andPF14_
0425, as described previously (64). The selection of Pf-iEsICAM and Pf-
iEsCD36 was confirmed using anti-ICAM-1 (10g/ml, 84H10; Chemicon)
and anti-CD36 (10 g/ml, FA6-152; Santa Cruz Biotechnology) mono-
clonal antibodies, respectively.
Static cytoadhesion assays.We assessed the ability of native or mod-
ified FucCS and other GAGs to inhibit the adhesion of Pf-iEsCSA, Pf-
iEsICAM, Pf-iEsCD36, and P. falciparum isolates to human lung endothelial
cells (HLECs) by performing static cytoadhesion assays, as described else-
where (34, 61, 65, 66), withminormodifications. Briefly, HLECs (5 104
cells) were grown to confluence on 8-well culture slides (each well, 0.69
cm2; Becton, Dickinson). We then added 5  104 Voluven-enriched Pf-
iEs per well in a total volume of 300 l of cytoadhesion medium (RPMI
1640 medium [pH 6.8]), alone or in the presence of increasing concen-
trations of heparin (Calbiochem, China), CSA, native FucCS, ormodified
FucCS structures (deFucCS andCRFucCS). Culture slides were incubated
for 1 h at 37°C and then extensively washed in cytoadhesion medium.
Alternatively, we performed static cytoadhesion assays on placenta cryo-
sections as described previously (54, 58, 65, 66), with minor modifica-
tions. Briefly, placental biopsy specimens from healthy pregnant women
were collected immediately after delivery, snap-frozen in liquid nitrogen/
n-hexane (Merck, Germany), and then stored frozen in Tissue-Tek
(Thermo) before use. Serial placenta cryosections (5 to 7 mm) were cut
with a cryotome and mounted on individual glass slides. Cryosections
were washed and air-dried, and an area of approximately 1 cm2 was de-
limited with a Dako-Pen device. Cytoadhesion assays were performed as
for endothelial cells; however, 1  105 Pf-iEsCSA were added to placenta
cryosections. The percent inhibition, relative to control (medium) values,
was determined by counting, with the aid of a microscope after Giemsa
staining, the number of Pf-iEs permm2 that adhered to an endothelial cell
monolayer or a placenta cryosection. Adhesion assays were performed at
least 2 or 3 times independently, and inhibitory values did not differ
significantly.
Flow-based cytoadhesion assays. The ability of FucCS to desequester
Pf-iEsCSA was assessed through flow-based cytoadhesion assays, as de-
scribed previously (54, 58). Briefly, HLECs (5  105) were cultured to
confluence in single-well culture slides (8.6 cm2; Becton, Dickinson);
then, 5 105 Pf-iEsCSA were added to the culture slides and were left for
static cytoadherence. After 1 h of incubation at 37°C, the culture slides
weremounted in a flow chamber system (Immunetics), and cytoadhesion
medium (control) or FucCS (100g/ml) was circulated at a shear stress of
0.09, 0.36, or 1.44 Pa, for 10, 5, or 2.5 min, respectively. For the flow
adhesion assay, enriched Pf-iEs (2 106) were subjected to the flow sys-
tem for 10min at a shear stress of 0.09 Pa. The culture slides were coupled
in the flow chamber system, through which passed cytoadhesionmedium
(control) or FucCS (100 g/ml) together with parasites. In both experi-
ments, the remaining adherent Pf-iEsCSA per mm2 were counted in 30
randomly chosen fields, which were captured using a 5.0-megapixel dig-
ital camera (Moticam 2500; Motic) adapted to the inverted microscope.
Rosette disruption assay. This assay was performed essentially as de-
scribed previously (36). Briefly, different concentrations of FucCS, de-
FucCS, heparin, or CSA were added to 18-l aliquots of a rosetting
FCR3S1.2 culture in a 96-well microtiter plate, which was then incubated
for 1 h at 37°C. FCR3S1.2 was also monitored over time (2, 10, 30, and 60
min) after treatment with 50 g/ml of FucCS or heparin, to examine the
kinetics of rosette disruption. A rosette was scored when a parasitized cell
bound to at least two noninfected red blood cells. Rosetting was assessed
after acridine orange (Sigma-Aldrich) staining. The percent rosetting, rel-
ative to control (medium) values, was expressed as follows: percent roset-
ting (no. of rosette-forming late-stage Pf-iEs/total no. of late-stage Pf-
iEs) 100.
Growth inhibition assays. The effects of FucCS, deFucCS, CRFucCS,
and otherGAGs onPf-iE developmentwere assessed by growth inhibition
assays (GIAs) (67). Briefly, synchronized young-stage forms (	24 h) of P.
falciparum cultures with 4% parasitemia and hematocrit levels were
grown for 24 or 48 h at 37°C in a 96-well microtiter plate in the presence
of increasing concentrations of GAGs. Parasite growth inhibition, ex-
pressed as a percentage of control (medium) values, was determined by
counting Pf-iEs in at least 1,000 cells on Giemsa-stained smears, under a
light microscope.
Merozoite invasion inhibition assay. Themerozoite invasion inhibi-
tion assay with native and modified FucCS, or other GAGs, was per-
formed as described previously (37), with modifications. In short, syn-
chronized late-stage forms (24 h) of P. falciparum cultures were grown
for 24 to 30 h at 37°C in a 96-well microtiter plate with increasing con-
centrations of GAGs, and parasite invasion inhibition was determined as
described for GIAs.
Statistical analysis. Statistical significance was determined using one-
way analysis of variance (ANOVA) or Student’s t test for parametric data.
Kruskal-Wallis and post hoc tests or theMann-WhitneyU test was used for
nonparametric data. All statistical analyses were performed using Prism
version 5.02 (GraphPad Software), and values were considered significant
at P	 0.05.
RESULTS
Effects of FucCS on P. falciparum cytoadherence and rosette
disruption. Based on the ability of various GAGs, including hep-
arin, to prevent parasite cytoadhesion, we assessed the cytoadher-
ence-inhibiting effect of FucCS using monophenotypic Pf-iEs
withHLECs and human placenta cryosections. To evaluate FucCS
toxicity, several concentrations of the compound were incubated
with HepG2 cells and noninfected erythrocytes (niEs). FucCS sig-
nificantly impaired hepatic cell growth only at a high concentra-
tion of 10,000g/ml, and no effect on niEs was observed at any of
the tested doses (see Fig. S1A and B in the supplemental material).
Thus, we analyzed the ability of FucCS to inhibit P. falciparum
cytoadherence to endothelial cells (Fig. 2). Indeed, FucCS abol-
ished cytoadherence in a dose-dependent manner similar to that
of heparin. The adhesion of parasites that bind to specific host
receptors, such as CSA (Pf-iEsCSA), ICAM-1 (Pf-iEsICAM), and
CD36 (Pf-iEsCD36), was inhibited by 99.1, 64.6, and 71.2%, respec-
tively (Fig. 2A to C). Moreover, at a concentration as low as 1
g/ml, FucCS was more efficient than heparin (Fig. 2A). As nat-
ural infections of P. falciparum often involve multiphenotypic
parasites (e.g., those binding to different receptors) (68, 69), we
examined whether FucCS could block the adhesion of fresh P.
falciparum isolates. According to Fig. 2D and E, FucCS also inhib-
ited adhesion of clinical isolates in a dose-dependent manner and
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was significantlymore effective than heparin at several tested con-
centrations.
Next, we investigated the major structural motifs in FucCS in-
volved in the inhibition of parasite adhesion, using two chemically
modified polysaccharides. As observed in Fig. 2F, both deFucCS and
CRFucCSwere significantly less effective than native FucCS in inhib-
iting Pf-iEsCSA adhesion. CRFucCS blocked parasite adhesion at
higher levels than did deFucCS (P 	 0.001), and similar effects
were noted for Pf-iEsICAM and Pf-iEsCD36 (see Fig. S2A and B in
the supplemental material).
Given that CSA is a receptor associated with MiP and that
FucCS abolished adhesion of Pf-iEsCSA, we evaluated the capacity
FIG 2 Effects of FucCS (native or modified) on the cytoadhesion of P. falciparum (laboratory strains or clinical isolates) to HLECs. P. falciparummonopheno-
typic laboratory strains Pf-iEsCSA (A), Pf-iEsICAM (B), and Pf-iEsCD36 (C) and clinical Amazonian isolates PfKA (D) and Pf38A (E) were incubated for 1 h at 37°C
on 8-well culture slides containing HLECs, in the presence or absence (control) of different concentrations of FucCS or heparin, or Pf-iEsCSA were incubated for
1 h at 37°C onHLECs in the presence of 100g/ml of native FucCS or themodified forms (deFucCS or CRFucCS) or culture medium alone (control) (F). Slides
were extensively washed, and bound Pf-iEs were counted after Giemsa staining. Inhibition was determined as a percentage, relative to control values, and results
are expressed as the means
 standard deviations (SD) of four wells from 2 independent assays. , P	 0.05; , P	 0.001 (ANOVA).
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of FucCS to inhibit the binding of this parasite to placenta cryo-
sections. As shown in Fig. 3, 100 g/ml of FucCS abrogated Pf-
iEsCSA adherence to the human placenta. We also evaluated the
effects of FucCS on parasite adhesion under flow conditions. As
shown in Fig. 4A, virtually no Pf-iEs adhered to HLECs under a
constant flow pressure of 0.09 Pa in a solution of 100 g/ml
FucCS. Importantly, FucCS, in comparison with the control (me-
dium), removed a significant amount of CSA-adherent parasites,
even under conditions of low shear stress (0.09 Pa) (Fig. 4B).
Having demonstrated the ability of FucCS to prevent parasite
binding under static and flow conditions, we investigated the dis-
ruptive effects of FucCS on P. falciparum rosettes (FCR3S1.2
strain). As seen in Fig. 5A, FucCS disrupted rosettes in a dose-
dependent manner and virtually abolished rosette formation,
even at low concentrations such as 10 g/ml. As observed in cy-
toadhesion assays, deFucCS proved to be less efficient than the
native compound in disrupting rosettes. We then evaluated how
quickly FucCS could disrupt rosettes by treating FCR3S1.2 cul-
tures with FucCS or heparin at different time points. As shown in
Fig. 5B, FucCS was able to disrupt rosettes at high levels within
only 2 min after its addition, similar to heparin.
Effects of FucCS on P. falciparum growth and erythrocyte
invasion. As previous studies have reported, GAGs, including
heparin, have major effects on parasite invasion (37, 40, 70, 71);
therefore, we investigated the action of FucCS on parasite devel-
opment by GIA. P. falciparum blood-stage parasites were incu-
bated with native or modified FucCS, as well as heparin or CSA,
for 48 h. As shown in Fig. 6A, similar to heparin, FucCS exhibited
dose-dependent inhibitory effects and completely abolished par-
asite development at concentrations of 100 and 1,000 g/ml. Im-
portantly, as noted in the cytoadhesion assays, CRFucCS signifi-
cantly hampered parasite development, whereas deFucCS did not.
Additionally, CSA inhibition was observed only at the highest
tested dose (1,000 g/ml). Then, to determine whether FucCS
could act on a specific parasite blood stage, we incubated synchro-
nous young-stage (	24 h postinvasion) forms of P. falciparum
with native or modified FucCS, as well as heparin or CSA. As seen
in Fig. 6B, neither FucCS (native ormodified) nor any of the tested
GAGs significantly inhibited ring-stage maturation.
Assuming that FucCS affects parasite development despite its
inability to stop ring-stage maturation, we analyzed the role of
FucCS in the invasion of noninfected erythrocytes (niEs) by P.
falciparum merozoites. As shown in Fig. 6C, CRFucCS but not
deFucCS significantly inhibited parasite invasion at 100 g/ml,
and FucCS or heparin hampered merozoite invasion in a dose-
dependent manner, at levels similar to those observed in GIAs,
after 48 h of incubation.
DISCUSSION
Here we show that FucCS exhibited marked inhibition of the
cytoadhesion of cultured Pf-iEs and clinical isolates to endo-
thelial cells and placenta cryosections under static and flow
conditions. FucCS was also highly effective in disrupting ro-
settes and interfering with parasite invasion. These results sug-
gest that FucCS may prove to be a useful adjunct therapy for
severe malaria.
The observed effects of FucCS on P. falciparum cytoadhesion
and invasion were very similar to those of heparin in most assays.
In fact, heparin displays potent inhibitory effects on Pf-iE cytoad-
herence and rosette formation in vitro (28, 36, 42, 72–74) and
remains the only sulfated glycoconjugate used to treat severe hu-
man malaria (75–77). However, despite some success as an ad-
FIG 4 FucCS inhibition, under flow conditions, of Pf-iECSA cytoadhesion and unbound adhered parasites on HLECs. (A) Enriched Pf-iEsCSA, in the presence of
FucCS (100 g/ml) or cytoadhesion medium only (control), were circulated for 10 min at 0.09 Pa on culture slides with HLECs coupled in the flow chamber
system. The results are expressed as the number of bound Pf-iEsCSA per square millimeter. (B) Alternatively, cytoadhesion medium (control) or FucCS (100
g/ml) flowed through single-wellmicroslides containingHLECswith adhered Pf-iEsCSA, under increasing shear stress conditions (0.09, 0.36, and 1.44 Pa). Data
are expressed as a percentage, relative to the adhesion at 0.00 Pa (control). In both situations, the remaining bound Pf-iEsCSA were counted in 30 randomly
selected fields. , P	 0.001 (Mann-Whitney test).
FIG 3 FucCS inhibition of adhesion of CSA-bound parasites to placenta.
Cultured P. falciparum parasites selected for CSA binding (Pf-iEsCSA) were
incubated at 37°C with placenta cryosections, with FucCS (100 g/ml) or
cytoadhesion medium (control). After 1 h, placental tissue samples were ex-
tensively washed, and adhered parasites were Giemsa stained and then visual-
ized and counted using a Nikon microscope at 100 magnification. The re-
sults are expressed as the mean
 SD of the number of bound Pf-iEsCSA/mm2
counted in at least 30 randomly selected fields after Giemsa staining. , P	
0.001 (Mann-Whitney test).
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junct treatment for complications of malaria (77–79), the use of
heparin was abandoned due to severe bleeding and the deaths of
some children under treatment (47).
When we analyzed the effects of modified compounds derived
from native FucCS, we noted marked differences between these
compounds (Fig. 2F; also see Fig. S2 in the supplemental mate-
rial). Although both modified FucCS structures exhibited inhibi-
tory cytoadhesion capacity that was significantly less than that of
FIG 5 FucCS disruption of P. falciparum rosettes. Rosetting parasite cultures (FCR3S1.2) were incubated for 1 h with or without (control) FucCS, deFucCS,
heparin, or CSA at various concentrations (A) or were treated with FucCS or heparin (both at 50g/ml) at different time points (2, 10, 30, and 60min) (B). The
percentage of rosetting, relative to control, was expressed as (no. of rosette-forming late-stage Pf-iEs)/(total no. of late-stage Pf-iEs) 100. Data are from one
representative experiment from three independent assays.
FIG 6 FucCS inhibition of P. falciparum growth (GIA) and merozoite invasion. Ring-synchronized P. falciparum-infected erythrocytes (A and B) or late-stage
forms (trophozoites) (C) cultured at 4% parasitemia and hematocrit levels were incubated at 37°C for 48 h (A) or 24 h (B and C) with increasing concentrations
of FucCS, heparin, CSA, or defucosylated (100 g/ml) or carboxyl-reduced (100 g/ml) modified FucCS. As a control, parasites were grown in RPMI 1640
medium. The percentage of growth inhibition was calculated relative to control values, and results are expressed as themeans
 SD of triplicates. , P	 0.05; ,
P	 0.01 (Kruskal-Wallis test).
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the native compound, deFucCS was nearly 3-fold less efficient
than CRFucCS. These findings demonstrate that the presence of
sulfated fucose branches in the native compound is critical for the
inhibition of Pf-iEs, and they corroborate previous observations
that removal of these branches abolishes the anticoagulant and
antithrombotic effects of FucCS (80). The presence of these
branches was essential for preserving the inhibitory effects of
FucCS in interactions mediated by P- and L-selectin (52), thus
indicating that these branches play a key role in supporting the
biological effects of FucCS.
Cytoadhesion of P. falciparum to CSA, and possibly other pla-
cental receptors, triggers host inflammatory processes, which in
turn affect placental function and contribute to the poor clinical
outcomes of MiP (18, 19). Based on this fact, CSA has previously
been considered for the adjunct treatment of malaria complica-
tions during pregnancy (41), due to its inhibitory effects on the in
vitro and in vivo cytoadherence of Pf-iEs (41). In this context, we
showed that FucCS was very efficient in inhibiting the adhesion of
Pf-iEsCSA to HLECs and virtually abolished adhesion to human
placenta. Additionally, FucCS was effective in preventing adhe-
sion and removing Pf-iEsCSA fromHLECs under flow conditions.
Apart from CSA (42, 72), rosettes can be disrupted by other
sulfated glycoconjugates, such as heparin (36, 38, 42), dextran
sulfate, and fucoidan (38, 72).Herewe have shown that FucCS has
effects that are similar to those of heparin, including the speed of
action for rosette disruption (Fig. 5). This action was dependent
on the sulfated fucose branches in the native structure of FucCS, as
deFucCS proved to be less effective than the native compound.
Studies have shown that heparin and other sulfated polysac-
charides (e.g., pentosan polysulfate, dextran sulfate, Curdlan sul-
fate, and fucoidan) inhibit the progression of P. falciparum
through its blood stages (40, 43, 71, 81, 82). Moreover, it has been
demonstrated that heparin and other GAGs, but not CSA (40, 42),
efficiently inhibit the invasion of erythrocytes by themerozoites of
different strains of P. falciparum (37, 40, 42, 43). Corroborating
these findings, we showed that FucCS inhibited continuous culti-
vation of P. falciparum in vitro (Fig. 6A), most likely by interfering
withmerozoite invasion (Fig. 6C) rather than by blocking parasite
development from the young- to late-stage forms, as assessed in
cultures of 24 and 48 h (Fig. 6A and B). In contrast, CSA did not
show any significant inhibitory effects onmerozoite invasion (Fig.
6C) and parasite development (Fig. 6A and B) except at the high-
est dose tested (1,000 mg/ml), which was most likely due to a
nonspecific effect of an excess of the compound in the medium.
These results agree with previous studies in which CSA had no
significant inhibitory effects on reinvasion, especially at lower
doses, with only marginal effects at high doses (40, 42).
Some studies have attempted to explain the mechanisms in-
volved in the inhibition of invasion by sulfated polysaccharides.
Clark and colleagues showed that only densely sulfated polysac-
charides (heparin, dextran sulfate, and fucoidan) were effective in
inhibiting parasite invasion (43), suggesting that inhibition was
the result of not only nonspecific ionic interactions but also a
particular conformation of anions present in the compounds.
Boyle and colleagues demonstrated that the level and pattern of
sulfation are crucial for the inhibitory activity of heparin and sim-
ilar compounds (83).
The effect of FucCS seems to be similar to that of heparin,
which inhibits parasite invasion, adhesion, and rosetting by bind-
ing to regions of PfEMP-1 and merozoite surface protein-1
(MSP-1) (83–85). Based on these findings, we hypothesized that
FucCS could block interactions of adhesion and invasion proteins
with host receptors that are glycoproteins expressed constitutively
in erythrocytes, most likely by binding to conserved regions of
these proteins, such as regionRII (86).Docking analyses are under
way to examine this hypothesis.
In addition to the effects described in this study, FucCS does
not require fractionation and/or chemical modification after pu-
rification (87) and is not derived frommammals (88), in contrast
to heparin and CSA, thus reducing the risk of contamination by
pathogens. Moreover, FucCS occurs at high concentrations in sea
cucumber and can be isolated with relatively high yields (approx-
imately 1% of the dry weight) (87). Also, it has weaker anticoag-
ulant and antithrombotic effects than heparin (48, 89) and acts, in
vitro and in vivo, at concentrations lower than those required to
trigger its anticoagulant effects (52). FucCS can also be adminis-
tered orally, which is another advantage in comparison with other
sulfated polysaccharides (90). Importantly, no toxic or cumula-
tive effects in tissue were observed after administration of FucCS
to animals at a daily dose of 50 mg/kg of body weight for 30 days
(M. S. G. Pavão and E. O. Kozlowski, unpublished data).
In conclusion, the observed similarities in the inhibitory effects
of FucCS and heparin on Pf-iE cytoadhesion, rosette formation,
and blockage of parasite invasion, as well as the unique sulfated
composition of FucCS, which confers advantages over other com-
pounds that have already been tested, raise hopes for the use of
FucCS in human trials as an adjunct therapy for the treatment of
several complications that characterize severe malaria.
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